Alexander Bystritsky, MD

Offices

2 locations · UC Regents · 148 clinicians in this group

Looking this up.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bystritsky’s office to ask if they take your plan before you enroll.

California Medical Board record

Licence A41302 · Current

Licensed to practise in California · since 1984 · expires 2028-01-31 · First Leningrad Medical Institute of I.P. Pavlova.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Drugs they prescribed that Part D paid

$2,220

Pharmacies billed $2,220 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 171) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.

165 generic and fewer than 11 brand-name prescriptions · $2,220 in drug cost · 12 antipsychotic prescriptions to people over 65.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Trazodone	25	$237	$9
Gabapentin	19	$167	$9
Eszopiclone	11	$156	$14
Zolpidem	12	$130	$11
Sertraline	22	$30	$1

See all 6 drugs

Sort by

Every Part D drug this clinician prescribed

Trazodone	25	$237	$9
Gabapentin	19	$167	$9
Eszopiclone	11	$156	$14
Zolpidem	12	$130	$11
Sertraline	22	$30	$1
Diazepam	13	$8	$1

Year by year

Sort by

Part D prescribing by year

2024	171	14	0% (0)	None	$2,220
2023	203	18	0% (0)	None	$4,485
2022	169	17	0% (0)	None	$7,140
2021	167	15	0% (0)	None	$8,073
2020	212	17	None	None	$7,227
2019	143	19	0% (0)	None	$8,705
2018	204	28	0% (0)	6%	$13,162
2017	461	29	0% (0)	3%	$19,530
2016	519	33	0% (0)	7%	$13,794
2015	438	23	None	14%	$21,484
2014	386	21	None	13%	$21,892
2013	439	22	None	13%	$30,662

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 8 drugs

Sort by

Part D drugs prescribed in 2023

Venlafaxine Hcl Er	18	$338	$19
Citalopram Hbr	11	$216	$20
Pregabalin	12	$205	$17
Trazodone	12	$171	$14
Zolpidem	12	$113	$9
Duloxetine	21	$48	$2
Sertraline	12	$28	$2
Diazepam	12	$26	$2

2022: 6 drugs

Sort by

Part D drugs prescribed in 2022

Fluoxetine	14	$512	$37
Trazodone	18	$139	$8
Zolpidem	14	$133	$9
Sertraline	13	$92	$7
Diazepam	12	$57	$5
Lorazepam	11	$45	$4

2021: 5 drugs

Sort by

Part D drugs prescribed in 2021

Aripiprazole	23	$4,079	$177
Zolpidem	17	$189	$11
Trazodone	17	$156	$9
Lorazepam	13	$54	$4
Diazepam	12	$27	$2

2020: 6 drugs

Sort by

Part D drugs prescribed in 2020

Aripiprazole	16	$1,608	$100
Memantine	12	$748	$62
Zolpidem	13	$122	$9
Trazodone	15	$104	$7
Lorazepam	15	$62	$4
Diazepam	12	$23	$2

2019: 4 drugs

Sort by

Part D drugs prescribed in 2019

Dextroamphetamine-Amphetamine	13	$750	$58
Bupropion Xl	14	$668	$48
Zolpidem	11	$71	$6
Risperidone	12	$24	$2

2018: 8 drugs

Sort by

Part D drugs prescribed in 2018

Bupropion Xl	14	$771	$55
Fluoxetine	13	$603	$46
Venlafaxine Hcl Er	16	$491	$31
Citalopram Hbr	16	$163	$10
Gabapentin	16	$121	$8
Zolpidem	12	$112	$9
Trazodone	14	$101	$7
Clonazepam	11	$26	$2

2017: 17 drugs

Sort by

Part D drugs prescribed in 2017

Lyrica	11	$5,215	$474
Bupropion Xl	32	$1,451	$45
Ziprasidone	33	$1,372	$42
Fluoxetine	36	$1,321	$37
Dextroamphetamine-Amphetamine	11	$889	$81
Quetiapine	25	$614	$25
Memantine	13	$481	$37
Gabapentin	46	$438	$10
Venlafaxine Hcl Er	31	$411	$13
Sertraline	23	$351	$15
Buspirone	27	$320	$12
Trazodone	37	$240	$6
Zolpidem	21	$125	$6
Escitalopram	19	$123	$6
Citalopram Hbr	15	$78	$5
Clonazepam	21	$55	$3
Lorazepam	13	$43	$3

2016: 17 drugs

Sort by

Part D drugs prescribed in 2016

Paxil Cr	20	$3,346	$167
Bupropion Xl	34	$1,420	$42
Ziprasidone	31	$1,306	$42
Quetiapine	39	$816	$21
Fluoxetine	41	$759	$19
Dextroamphetamine-Amphetamine	12	$627	$52
Venlafaxine Hcl Er	31	$593	$19
Memantine	14	$532	$38
Gabapentin	34	$323	$10
Sertraline	43	$310	$7
Buspirone	15	$282	$19
Trazodone	33	$191	$6
Escitalopram	14	$123	$9
Zolpidem	25	$99	$4
Citalopram Hbr	24	$93	$4
Clonazepam	38	$90	$2
Lorazepam	14	$37	$3

2015: 17 drugs

Sort by

Part D drugs prescribed in 2015

Paxil Cr	22	$3,378	$154
Ziprasidone	26	$1,560	$60
Bupropion Xl	34	$1,231	$36
Quetiapine	17	$1,124	$66
Bupropion	13	$709	$55
Zolpidem	19	$419	$22
Venlafaxine Hcl Er	40	$377	$9
Risperidone	13	$244	$19
Gabapentin	26	$223	$9
Trazodone	27	$215	$8
Sertraline	36	$201	$6
Buspirone	14	$179	$13
Fluoxetine	12	$146	$12
Clonazepam	34	$116	$3
Lorazepam	14	$86	$6
Lamotrigine	12	$85	$7
Citalopram Hbr	11	$47	$4

2014: 14 drugs

Sort by

Part D drugs prescribed in 2014

Ziprasidone	25	$4,618	$185
Paxil Cr	21	$3,070	$146
Quetiapine	14	$1,729	$123
Venlafaxine Hcl Er	30	$1,019	$34
Bupropion	18	$685	$38
Clonazepam	55	$664	$12
Methylphenidate	12	$640	$53
Bupropion Xl	18	$576	$32
Sertraline	22	$324	$15
Gabapentin	22	$226	$10
Zolpidem	32	$204	$6
Lamotrigine	13	$127	$10
Citalopram Hbr	13	$115	$9
Trazodone	16	$74	$5

2013: 18 drugs

Sort by

Part D drugs prescribed in 2013

Ziprasidone	34	$7,041	$207
Quetiapine	21	$3,506	$167
Namenda	14	$2,009	$143
Paxil Cr	13	$1,804	$139
Bupropion	16	$1,198	$75
Bupropion Xl	19	$849	$45
Methylphenidate	12	$761	$63
Venlafaxine Hcl Er	18	$652	$36
Buspirone	13	$537	$41
Thiothixene	11	$517	$47
Sertraline	30	$501	$17
Clonazepam	46	$481	$10
Gabapentin	29	$410	$14
Citalopram Hbr	17	$295	$17
Lamotrigine	18	$293	$16
Venlafaxine	13	$237	$18
Zolpidem	32	$186	$6
Lorazepam	14	$56	$4

Money from drug and device companies

$6,860 in 2025

Sort by

Industry payments by year

2025	2	2	$6,837	$6,860
2024	1	1	$806	$806
2022	4	11	None	$1,162
2020	5	9	None	$167
2019	4	8	None	$251

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Otsuka Pharmaceutical Development & Commercialization	None	$6,837	1 payment Consulting · 2025-01-09 · $6,837
Janssen Pharmaceuticals	Spravato	$23	1 payment Meals for Spravato · 2025-10-27 · $23

See all 2 published payments

Sort by

Every published payment

Janssen Pharmaceuticals	Meals · 2025-10-27	Spravato	$23
Otsuka Pharmaceutical Development & Commercialization	Consulting · 2025-01-09	None	$6,837

See earlier years (2024, 2022, 2020, 2019)

2024: $806

Sort by

Payments by company in 2024

Otsuka Pharmaceutical Development & Commercialization	None	$806	1 payment Consulting · 2024-10-08 · $806

2022: $1,162

Sort by

Payments by company in 2022

Boehringer Ingelheim Pharmaceuticals	None	$1,040	7 payments Travel · 2022-07-14 · $489 Meals · 2022-07-14 · $50 Meals · 2022-07-14 · $144 Meals · 2022-07-14 · $35 Meals · 2022-07-14 · $60 Meals · 2022-07-14 · $35 Travel · 2022-07-14 · $227
Sunovion Pharmaceuticals	None	$84	2 payments Meals · 2022-12-06 · $20 Meals · 2022-12-05 · $64
Biohaven Pharmaceutical Holding Company	Nurtec Odt	$24	1 payment Meals for Nurtec Odt · 2022-06-01 · $24
Vanda Pharmaceuticals	Hetlioz	$14	1 payment Meals for Hetlioz · 2022-05-11 · $14

2020: $167

Sort by

Payments by company in 2020

Sunovion Pharmaceuticals	Latuda	$55	3 payments Meals for Latuda · 2020-03-12 · $13 Meals for Latuda · 2020-02-21 · $23 Meals for Latuda · 2020-01-10 · $19
Adlon Therapeutics L.P.	Adhansia Xr	$40	2 payments Meals for Adhansia Xr · 2020-07-09 · $24 Meals for Adhansia Xr · 2020-02-27 · $16
Avanir Pharmaceuticals	Nuedexta	$37	2 payments Meals for Nuedexta · 2020-03-05 · $22 Meals for Nuedexta · 2020-01-29 · $15
Lundbeck	Brintellix	$20	1 payment Meals for Brintellix · 2020-02-06 · $20
Novo Nordisk	Saxenda	$14	1 payment Meals for Saxenda · 2020-01-23 · $14

2019: $251

Sort by

Payments by company in 2019

Takeda Pharmaceuticals U.S.A.	Trintellix	$119	2 payments Meals for Trintellix · 2019-09-11 · $20 Meals · 2019-05-29 · $99
Vanda Pharmaceuticals	Fanapt	$58	2 payments Meals for Fanapt · 2019-08-28 · $29 Meals for Fanapt · 2019-06-21 · $29
Novo Nordisk	Saxenda	$49	3 payments Meals for Saxenda · 2019-12-12 · $14 Meals for Saxenda · 2019-10-07 · $20 Meals for Saxenda · 2019-07-26 · $14
Merz North America	Xeomin	$25	1 payment Meals for Xeomin · 2019-10-14 · $25

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Janssen Research & Development, LLC · A Study of Esketamine Nasal Spray Administered As Monotherapy in Adult Participants With Treatment Resistant Depression · 2023	Their institution	$94,790
Janssen Research & Development, LLC · A Study of Esketamine Nasal Spray Administered As Monotherapy in Adult Participants With Treatment Resistant Depression · 2021	Their institution	$92,877
Boehringer Ingelheim Pharmaceuticals, Inc. · Pocc Study in Patients With Ptsd · 2023	Their institution	$89,947
Janssen Research & Development, LLC · A Study of Esketamine Nasal Spray Administered As Monotherapy in Adult Participants With Treatment Resistant Depression · 2022	Their institution	$81,767
Biohaven Pharmaceuticals, Inc. · A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder · 2021	Their institution	$60,477
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. · 2019	Their institution	$44,393
Brainsway USA INC · Brainsway Deep Tms · 2022	This clinician	$39,979
Boehringer Ingelheim Pharmaceuticals, Inc. · Pocc Study in Patients With Ptsd · 2022	Their institution	$33,908
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder · 2021	Their institution	$32,160
Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 Mg in Adults With Major Depressive Disorder · 2019	Their institution	$30,545
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Iti-1284 As An Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have An Inadequate Response To Generalized Anxiety Disorder Treatment · 2025	Their institution	$30,273
Biohaven Pharmaceutical Holding Company Ltd. · A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder · 2022	Their institution	$23,143
Janssen Research & Development, LLC · A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjunctive Aticaprant Plus An Antidepressant for Relapse Prevention in Major Depressive Disorder (Mdd) With Moderate-To-Severe Anhedonia Ventura-5 · 2025	Their institution	$20,724
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. · 2020	Their institution	$18,127
Boehringer Ingelheim Pharma GmbH & Co.KG · Pocc Study in Patients With Ptsd · 2022	Their institution	$14,909
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder · 2021	Their institution	$13,626
Janssen Research & Development, LLC · A Study of Esketamine Nasal Spray Administered As Monotherapy in Adult Participants With Treatment Resistant Depression · 2024	Their institution	$13,212
Biohaven Pharmaceuticals, Inc. · A Multicenter 48-Week Open-Label Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder · 2021	Their institution	$12,732
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Open-Label Trial To Evaluate the Safety and Tolerability of Brexpiprazole · 2021	Their institution	$11,715
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite · 2020	Their institution	$10,057
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. · 2021	Their institution	$7,729
Biohaven Pharmaceutical Holding Company Ltd. · A Multicenter 48-Week Open-Label Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder · 2022	Their institution	$7,008
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder · 2022	Their institution	$6,920
Avanir Pharmaceuticals, Inc. · 2021	Their institution	$6,520
AMAG Pharmaceuticals, Inc. · Prasterone Dhea for the Treatment of Hypoactive Sexual Desire Disorder Hsdd - Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone · 2019	Their institution	$6,203
Boehringer Ingelheim Pharmaceuticals, Inc. · Pocc Study in Patients With Ptsd · 2024	Their institution	$6,062
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6 Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type · 2024	Their institution	$5,800
ABBVIE INC. · A Study To Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder · 2025	Their institution	$4,150
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder · 2022	Their institution	$2,878
Boehringer Ingelheim Pharma GmbH & Co.KG · Pocc Study in Patients With Ptsd · 2023	Their institution	$2,266
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Open-Label Trial To Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Borderline Personality Disorder. · 2022	Their institution	$1,405
Otsuka Pharmaceutical Development & Commercialization, Inc. · Brexpiprazole As Combination Therapy With Sertraline in Treatment of Adults With Ptsd · 2019	This clinician	$1,330
ABBVIE INC. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder · 2024	Their institution	$840

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 91.7 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1053428011
Licence: CA A41302California A41302: Current · expires 2028-01-31
Group: UC Regents
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Psychiatry (2084P0800X)
Mailing address: 5767 W Century Blvd Ste 400, Los Angeles, CA, 90045
NPI first listed: 2006-08-24
NPI last updated: 2024-07-19
NPI record certified: 2024-07-19

This is when the NPI record was last certified, not a medical board exam.